Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Bicara Therapeutics Inc. ( (BCAX) ).
On December 6, 2025, Bicara Therapeutics announced preliminary data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizumab for treating HPV-negative recurrent/metastatic head and neck squamous cell carcinoma. The data, presented at the ESMO Asia Congress, showed a 57% overall response rate with a safety profile consistent with known data. Additionally, new biomarker data indicated that a higher dose of 1500mg resulted in greater TGF-β inhibition and deeper tumor responses, suggesting more durable patient outcomes. The company plans to declare the optimal biologic dose for the pivotal FORTIFI-HN01 study in early 2026.
The most recent analyst rating on (BCAX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Bicara Therapeutics Inc. stock, see the BCAX Stock Forecast page.
Spark’s Take on BCAX Stock
According to Spark, TipRanks’ AI Analyst, BCAX is a Neutral.
Bicara Therapeutics’ stock score reflects its high-risk profile typical of early-stage biotechnology companies. The primary concern is the lack of revenue and dependence on external funding, but a strong cash position provides some financial stability. The technical analysis shows positive momentum, though investors should be cautious of potential overbought conditions. Traditional valuation metrics are not applicable, emphasizing the importance of monitoring R&D progress and market sentiment.
To see Spark’s full report on BCAX stock, click here.
More about Bicara Therapeutics Inc.
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing transformative bifunctional therapies for patients with solid tumors. Their lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to enhance tumor penetration by targeting the tumor microenvironment, specifically for head and neck squamous cell carcinoma and other solid tumor types.
Average Trading Volume: 668,713
Technical Sentiment Signal: Strong Buy
Current Market Cap: $997M
For an in-depth examination of BCAX stock, go to TipRanks’ Overview page.